AIGH Capital Management LLC Acquires 253,727 Shares of PolyPid Ltd. $PYPD

AIGH Capital Management LLC grew its holdings in shares of PolyPid Ltd. (NASDAQ:PYPD) by 27.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,194,108 shares of the company’s stock after buying an additional 253,727 shares during the quarter. PolyPid makes up 1.9% of AIGH Capital Management LLC’s portfolio, making the stock its 21st largest position. AIGH Capital Management LLC owned about 0.12% of PolyPid worth $4,215,000 as of its most recent SEC filing.

Wall Street Analysts Forecast Growth

Several brokerages have commented on PYPD. Wall Street Zen raised shares of PolyPid from a “sell” rating to a “hold” rating in a research report on Friday, September 26th. HC Wainwright reissued a “buy” rating and set a $13.00 price target on shares of PolyPid in a research report on Wednesday, August 13th. Roth Capital reaffirmed a “buy” rating on shares of PolyPid in a report on Thursday, August 14th. Craig Hallum reaffirmed a “buy” rating and issued a $13.00 target price (down from $15.00) on shares of PolyPid in a report on Thursday, August 14th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PolyPid in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $12.40.

PolyPid Stock Performance

Shares of PYPD stock opened at $3.27 on Monday. The firm’s 50-day moving average is $3.41 and its 200-day moving average is $3.22. The stock has a market cap of $51.99 million, a price-to-earnings ratio of -0.85 and a beta of 1.50. PolyPid Ltd. has a 52-week low of $2.30 and a 52-week high of $3.93.

PolyPid (NASDAQ:PYPD) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.25). Sell-side analysts predict that PolyPid Ltd. will post -1.79 EPS for the current fiscal year.

PolyPid Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.